AtriCure, Inc. develops surgical and minimally invasive technologies for atrial fibrillation, left atrial appendage management and post-operative pain management. Company updates commonly cover quarterly and annual financial results, U.S. and international revenue trends, product adoption for AtriClip, cryoSPHERE, EnCompass and related device families, and clinical programs tied to Afib treatment and pain-blocking cryoablation.
Its disclosed product portfolio includes the FDA-approved Isolator Synergy Ablation System for persistent Afib, AtriClip Left Atrial Appendage Exclusion System products, Hybrid AF Therapy, and cryoICE cryoSPHERE and cryoXT probes for temporary peripheral nerve ablation.
AtriCure (ATRC) reported third-quarter 2026 revenue of $154.5 million, up 15.0% year over year, alongside a return to net profit.
Net income was $4.1 million, or $0.08 per basic and diluted share, versus a $0.01 per-share loss a year earlier. Gross margin rose 180 basis points to 77.3%. Adjusted EBITDA, a non-GAAP measure of earnings excluding specified expenses, increased 51% to $26.8 million. U.S. revenue grew 17.1% to $128.0 million; international revenue rose 5.8% to $26.4 million. Minimally invasive ablation sales declined as Hybrid procedures decreased.
Management projects full-year revenue of approximately $606 million to $610 million, adjusted EBITDA of approximately $91 million to $94 million, net income per share of $0.21 to $0.27 and adjusted earnings per share of approximately $0.40 to $0.46. It also expects continued positive cash generation for 2026.
AtriCure (Nasdaq: ATRC) will participate in two upcoming investor conferences, with management scheduled for fireside discussions at both events.
The UBS Global Healthcare Conference discussion is scheduled for November 9, 2026, at 11:00 a.m. Eastern Standard Time. The Stifel Healthcare Conference discussion is scheduled for November 11, 2026, at 1:20 p.m. Eastern Standard Time. Live audio webcasts will be available through the company’s investor website.
AtriCure (ATRC) will release its third quarter 2026 financial results on November 3, 2026, and host a webcast that day.
The audio webcast to discuss the results begins at 4:30 p.m. Eastern Time. Live and replay versions will be available on the company’s investor relations website.
S&P Dow Jones Indices will rebalance the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 before the market opens on September 21, 2026, to keep each index aligned with its target market-cap range.
Dell Technologies, Palo Alto Networks, Arista Networks, and Sandisk will join the S&P 100, while NIKE, Honeywell Aerospace, Simon Property Group, and Colgate-Palmolive exit. Bloom Energy, Everpure, and Illumina will enter the S&P 500, replacing Molson Coors Beverage, The Trade Desk, and Builders FirstSource, which move to the S&P SmallCap 600. Multiple constituents, including HubSpot, AGNC Investment, Corcept Therapeutics, Brinker International, Herc Holdings, Delek US Holdings, AXT, Arcutis Biotherapeutics, AtriCure, Capri Holdings, Boston Beer, and others shift among the S&P MidCap 400 and S&P SmallCap 600.
AtriCure (Nasdaq: ATRC) announced its participation in the 2026 Wells Fargo Health Care Conference. Company management is scheduled for a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. EST. A live audio webcast will be available via the Investors section of AtriCure’s website.
AtriCure (Nasdaq: ATRC) announced participation in two investor conferences in August 2026. Management will hold meetings at the 11th Annual Needham Virtual MedTech & Diagnostics Conference on August 10, 2026, and attend the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026.
At the Canaccord event, management will host a fireside chat at 11:30 a.m. EST. A live audio webcast will be available through the Investors section of AtriCure’s website at https://ir.atricure.com.
AtriCure (Nasdaq: ATRC) reported second quarter 2026 worldwide revenue of $153.6 million, up 12.8% year over year (12.4% constant currency). U.S. revenue rose to $125.6 million (+13.6%), driven by cryoSPHERE MAX pain management probes, EnCompass clamps, and AtriClip FLEX-Mini and PRO-Mini devices. International revenue grew 9.6% to $28.0 million.
Gross profit reached $118.6 million with gross margin of 77.2%, up 269 basis points, and income from operations was $9.7 million versus a prior-year loss. Net income was $9.0 million, or $0.18 per basic and diluted share, compared to a loss of $0.13 per share. Adjusted EBITDA increased 78% to $27.3 million, and second quarter cash generation was $21.6 million. For full year 2026, AtriCure projects revenue of $602–$610 million, adjusted EBITDA of $85–$89 million, GAAP EPS of $0.05–$0.13, and adjusted EPS of $0.24–$0.32, with continued positive cash generation.
AtriCure (Nasdaq: ATRC) will release its second quarter 2026 financial results on Thursday, July 23, 2026. The company develops surgical treatments for atrial fibrillation, LAA management, and post-operative pain.
An audio webcast to discuss the Q2 2026 results is scheduled for 4:30 p.m. Eastern Time the same day, with live and replay access via AtriCure’s investor relations events webpage.
AtriCure (Nasdaq: ATRC) will participate in the Goldman Sachs 47th Annual Global Health Care Conference. Management is scheduled for a fireside chat on Wednesday, June 10, 2026, at 8:40 a.m. EST.
A live audio webcast will be available in the Investors section of AtriCure's website.
AtriCure (Nasdaq: ATRC) reported Q1 2026 revenue of $141.2 million, up 14.3% year‑over‑year (12.8% constant currency). U.S. revenue was $116.2 million (+14.9%). Gross margin improved to 77.4%, net income was $0.1 million and adjusted EBITDA was $17.1 million. Management guided full‑year 2026 revenue of $600–$610 million, adjusted EBITDA of $80–$82 million, and adjusted EPS of $0.00–$0.04.